Pharma BD Deal Intelligence
Bamboo's lead gene therapy failed Phase 3 in 2024, triggering a $230-240M writedown, NC layoffs, and a facility fire-sale — Pfizer has now zeroed out its entire gene therapy portfolio built on this platform.
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Headline frames Pfizer as 'doubling down' on gene therapy; coverage emphasizes the deal enhancing Pfizer's leadership position in gene therapy through Bamboo's…
GEN highlighted Pfizer SVP Mikael Dolsten's view that gene therapy 'may hold the promise of bringing true disease modification' and characterized the Bamboo…
Pfizer ended development of its Bamboo-derived DMD gene therapy after the Phase 3 CIFFREO study missed all objectives, took a $230M impairment, and cut…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Pfizer acquired Chapel Hill, NC-based Bamboo Therapeutics, a gene therapy company. Pfizer previously took ~22% stake for $43M in Q1 2016, then acquired remaining equity for $150M upfront plus up to $495M in milestone payments tied to development, regulatory, and commercial progression (~$645M total). Adds clinical and preclinical AAV gene therapy assets, vector platform, and Phase I/II manufacturing facility (acquired from UNC).
Bamboo's lead gene therapy failed Phase 3 in 2024, triggering a $230-240M writedown, NC layoffs, and a facility fire-sale — Pfizer has now zeroed out its entire gene therapy portfolio built on this platform.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Bamboo Therapeutics, Inc. (this deal) | 2016 | $645M | 13 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2016 deals · Pfizer Inc. deals · Neurology deals